Why the Biocidal Products Regulation Decides Whether Your Coils Clear EU Customs
Demand for mosquito coils across Europe is climbing fast. The European Centre for Disease Prevention and Control (ECDC) reports that the Aedes albopictus tiger mosquito is now established in 16 EU/EEA countries and 369 regions, and Grand View Research values the European insect-repellent market at roughly US$2 billion in 2025, growing around 6.4% a year, with mosquito repellent the largest segment. That is a genuine opening for importers and private-label brands. But before a single carton reaches a shelf, it has to clear one gatekeeper: the EU Biocidal Products Regulation. A mosquito coil is a biocidal product, and the biocidal products regulation — formally Regulation (EU) 528/2012, or BPR EU 528/2012 — governs which active substances may be used, who may place the product on the market, and how it must be labelled. The single most expensive mistake we see European buyers make is assuming a coil that sells freely in Asia can be imported into Europe unchanged. It often cannot, and the reason is usually the active ingredient. This guide walks through the mosquito coil EU regulations that matter most when importing mosquito repellent into Europe: the banned active that gets shipments rejected, the compliant alternative, the Article 95 supplier rule, labelling, and the UK's now-separate regime.
The d-Allethrin Ban EU Importers Keep Missing
For decades, d-allethrin (also marketed as esbiothrin) has been one of the most common active substances in mass-market mosquito coils, and it remains widely used by factories across Asia. That is exactly the problem for EU importers. Under Commission Implementing Decision (EU) 2023/470, d-allethrin was not approved for product-type 18 (PT18, insecticides) under the Biocidal Products Regulation. The practical effect is blunt: since 26 March 2023, mosquito coils containing d-allethrin as their insecticidal active can no longer be legally placed on the EU market. This is the d-allethrin ban EU buyers most often discover too late — after a container is already in transit or held at customs. Because d-allethrin coils are cheap, abundant, and still perfectly legal in many producing countries, a supplier acting in good faith may quote you a product that simply cannot enter Europe. A quote, a sample, or even a long track record of sales elsewhere is not evidence of EU compliance. Before you commit to any coil, the first question to ask your manufacturer is which active substance the formulation uses and whether that active is currently approved for PT18 under the BPR. If the answer is d-allethrin, the conversation should stop there for the EU market.
Transfluthrin: The BPR-Approved Mosquito Coil Active
If d-allethrin is out, what is in? For coils, the clearest compliant route is transfluthrin. Transfluthrin remains an approved active substance for product-type 18 under the Biocidal Products Regulation, and Commission Implementing Decision (EU) 2025/1806 extended its approval expiry to 30 April 2028 — giving importers several years of regulatory certainty to build a product line around it. A transfluthrin mosquito coil formulated to the correct dosage is, from an active-substance standpoint, on far safer ground for the EU market than a d-allethrin equivalent. Other pyrethroids such as metofluthrin are also used in modern coils and may hold approvals of their own, but active-substance approvals are reviewed and renewed on their own timelines, so you should confirm the current status of any specific active on ECHA's records rather than assume it. The key point for buyers is that being 'transfluthrin-based' is not a marketing phrase to take on trust either — you need documentation showing the exact active, its concentration, and its approval status. As an OEM manufacturer, QCI can formulate coils around transfluthrin and supply the accompanying technical documentation, so the product you order is built for EU approval from the formulation stage rather than reworked after a rejection. You can explore our coil range to see the formats available.
The Article 95 List: A Biocidal Products Regulation Rule First-Time Importers Miss
Getting the active substance right is necessary but not sufficient. The Biocidal Products Regulation also controls who is allowed to place the product on the market. Under Article 95 of BPR EU 528/2012, a biocidal product cannot be made available on the EU market unless a relevant party in the supply chain — the active-substance supplier, the product manufacturer, or the EU importer — appears on ECHA's Article 95 list for the relevant active and product type. In plain terms, even a perfectly formulated transfluthrin coil cannot be sold legally if nobody in your chain is Article 95-listed for that active. Many first-time importers have never heard of the Article 95 list until a distributor or an enforcement authority asks for the reference. On top of Article 95, the product itself generally requires authorisation — biocidal products need product authorisation through ECHA or the relevant national competent authority before they can be marketed, according to guidance summarising the BPR. This is where sourcing from a manufacturer that already understands the regulation pays off. Verify early where your supply chain sits relative to the Article 95 list and what authorisation route applies in your destination country, and if any of it is unclear, confirm the specifics with ECHA or a qualified regulatory consultant before you order.
Labelling: BPR Article 69 Plus the CLP Regulation
A coil can hold a compliant active and still be rejected on its label. Biocidal products sold in the EU are regulated on labelling from two directions at once. First, Article 69 of the Biocidal Products Regulation sets out the mandatory information a biocidal product label must carry. Second, the product must be classified, labelled, and packaged under the CLP Regulation, which governs hazard pictograms, signal words, and hazard and precautionary statements. National authorities enforce the detail: Sweden's Chemicals Agency (Kemikalieinspektionen, or KEMI), for example, publishes specific requirements for the content of biocidal product labels, and packaging designed outside the EU frequently fails on exactly these points. Artwork that looks polished but omits a required warning, uses the wrong pictogram, or is not in the destination market's language is a common reason coils get held or refused. This matters especially for private-label and own-brand programmes, where the packaging is the whole point. The safest approach is to design the label to BPR Article 69 and CLP requirements from the start, in the correct language for each market, rather than translating and retrofitting after the fact. Because label rules can vary in the detail from country to country, treat national competent authority guidance as the final word and verify before you print a large run.
Selling into Great Britain? GB BPR Is Now a Separate Rulebook
If your plan includes the United Kingdom, be aware that EU and UK compliance are no longer the same exercise. Since 31 December 2020, Great Britain has operated its own GB Biocidal Products Regulation, administered by the Health and Safety Executive (HSE) rather than ECHA. The structure is familiar — insecticidal coils fall under product-type 18 and repellents under product-type 19 — but the decisions are made independently, and they are starting to diverge. The HSE has issued its own active-substance non-approval decisions, with some taking effect in April 2026, which means an active's status in Great Britain will not necessarily match its status in the EU. For an importer targeting both markets, that can mean maintaining two compliance dossiers and, potentially, two product variants. Northern Ireland's position can differ again, so do not assume 'the UK' is a single market. The takeaway is not that the UK is closed — it is that you must check GB BPR requirements through the HSE separately from the EU BPR, rather than assuming an EU-compliant coil automatically qualifies for Great Britain or vice versa. As the two regimes drift apart over the coming years, verifying the current position with the HSE for GB and ECHA for the EU becomes part of routine sourcing diligence.
Your Mosquito Coil EU Regulations Compliance Checklist
Pulling it together, here is the practical sequence for importing mosquito repellent into Europe without nasty surprises at customs. One, confirm the active substance: reject d-allethrin for the EU market, and prefer an active approved for PT18 such as transfluthrin, whose approval currently runs to 30 April 2028 under Decision (EU) 2025/1806. Two, get documentation: insist on written confirmation of the exact active, its concentration, and its approval status — not verbal assurances. Three, check Article 95: make sure a party in your supply chain is on ECHA's Article 95 list for that active and product type. Four, secure product authorisation: confirm the ECHA or national authorisation route for each destination country before you order. Five, get the label right: design to BPR Article 69 and the CLP Regulation from the outset, in the correct language, with the correct pictograms and warnings. Six, handle the UK separately: if you sell into Great Britain, verify GB BPR status with the HSE, because non-approvals there are diverging from April 2026. Seven, when anything is uncertain, verify with ECHA, the relevant national competent authority, the HSE, or a qualified regulatory consultant — this guide is a practical orientation, not legal advice. Working through this list before you place an order is far cheaper than discovering a problem when your container is already at port.
Partner with QCI for EU-Compliant Mosquito Coils
The reason so many coils fail EU compliance is that they were never formulated for Europe in the first place. That is the gap QCI closes. As a Malaysian OEM and private-label mosquito coil manufacturer, Quality Coils Industries (QCI) formulates coils around EU-approved actives such as transfluthrin, supplies the technical documentation importers need for BPR and Article 95 questions, and produces private-label packaging designed to BPR Article 69 and CLP labelling requirements rather than reworked after a rejection. Whether you are a first-time importer sizing up the European opportunity or an established brand owner replacing a non-compliant d-allethrin line, we can build a product that is engineered to clear customs and perform on the shelf. We can also advise on variants for the EU and Great Britain where the two regimes differ. Learn how our OEM model de-risks your supply chain on our OEM advantage page, and when you are ready to specify a compliant coil for your market, contact our team to discuss formulation, documentation, and packaging. Note that this article is general guidance, not legal advice — always confirm current requirements with ECHA, the HSE, or a regulatory professional for your specific product and destination market.